Skip to main content
Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: Extracellular matrix turnover biomarkers reflect pharmacodynamic effects and treatment response of adalimumab in patients with axial spondyloarthritis—results from two randomized controlled trials

Fig. 2

The pharmacodynamic effect of ADA treatment in the DANISH and ASIM studies. Percentage (%) change from baseline of the placebo group vs the ADA group of the selected ECM biomarkers. A.1–G.1 DANISH study. A.2–G.2 ASIM study. p-values at weeks 12 and 6 were adjusted for multiple comparisons by the false rate discovery method, and a significant difference is displayed by the following asterisks: *p < 0.05, **p < 0.01, ***p < 0.001. Dashed points determine the crossover from placebo to active ADA treatment. Data are presented as mean ± standard error of the mean. Only biomarkers that obtained significance in the analyses are shown here; the rest are provided in Additional file 1: Fig. S1. Abbreviations: C1M, metalloproteinase (MMP)-2/9/13-degraded type I collagen; C3M, MMP-degraded type III collagen; C4M, MMP (multiple)-degraded type IV collagen; C6M, MMP-2/9-degraded type VI collagen; PRO-C4, type IV 7S domain collagen; CPa9-HNE, HNE-mediated degradation of calprotectin

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us